GXO Logistics Inc vs Smith & Nephew plc — how do they compare? GXO Logistics Inc trades at $52.24 (market cap $6.02B), while Smith & Nephew plc trades at $30.69 (market cap $12.81B). The key difference: Smith & Nephew plc is far larger — about 2.1× GXO Logistics Inc's market cap, and Smith & Nephew plc pays a 2.54% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals.
| GXO | SNN | |
|---|---|---|
Market Cap | $6.02B | $12.81B |
Sector | Industrials | Health |
52-Week High | $65.59 | $38.70 |
52-Week Low | $45.52 | $28.73 |
Enterprise Value | $11.18B | $15.58B |
Dividend Yield | — | 2.54% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.
Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →